The maximum tolerated dose was not reached with ifinatamab deruxtecan; however, one death due to treatment-related interstitial lung disease highlights the importance of prompt evaluation and careful management of patients who develop interstitial lung disease. Promising antitumour activity was observed across various solid tumours. These findings support further evaluation of ifinatamab deruxtecan in randomised controlled trials.
[Articles] Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
The Lancet Oncology | | Melissa L Johnson, Manish R Patel, Gerald S Falchook, Takafumi Koyama, Martin Gutierrez, Mark M Awad, Sarina A Piha-Paul, Claire F Friedman, Taroh Satoh, Naoko Okamoto, Jasmeet Singh, Naoto Yoshizuka, Hillarie Plessner Windish, Meng Qian, Brittany P Tran, Toshihiko Doi
Topics: clinical-trials, research